Log in to search using one of your social media accounts:

 

European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland Approval base... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, Pfizer, BAVENCIO, avelumab, Merkel cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2017 Category: Pharmaceuticals Source Type: news

Nestle to cut jobs at French skin health R & D center
ZURICH (Reuters) - Nestle plans to cut up to 450 jobs at a Galderma research and development center in southern France, the Swiss company said on Thursday, as it seeks to make the underperforming skin health business more efficient. (Source: Reuters: Health)
Source: Reuters: Health - September 21, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Invitation to Roche's 9 Months Sales 2017 Audio Webcast and Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2017 prior to the opening of the Swiss Stock Exchange on Thursday October 19th, 2017. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2017 Category: Pharmaceuticals Source Type: news

These Are the 10 Best International Airports
This article originally appeared on TravelandLeisure.com (Source: TIME.com: Top Science and Health Stories)
Source: TIME.com: Top Science and Health Stories - September 20, 2017 Category: Consumer Health News Authors: Christopher Tkaczyk / Travel + Leisure Tags: Uncategorized onetime onetimetravel Source Type: news

‘This Is All We Can Do’: How the Japanese Are Preparing for a North Korean Nuclear Attack
The wail of the emergency siren reverberates across the school’s playing field, conjuring a primal fear even before the words “Missile launched! Missile launched!” crackle over the loudspeaker. Two dozen men, women and children—many wearing bonnets and wet neck towels against the blazing sunshine—scamper across the shingle expanse before squatting down low with arms covering heads. “We haven’t got a nuclear shelter or even strong buildings, so this is all we can do,” says Nakamura Takashi, an official of Sakura City in Japan’s central Tochigi Prefecture, who helped to o...
Source: TIME.com: Top Science and Health Stories - September 20, 2017 Category: Consumer Health News Authors: Charlie Campbell / Tokyo Tags: Uncategorized Japan onetime Source Type: news

Novartis's Rydapt wins EU approval for AML, other diseases
ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April. (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Rapid Medical launches Tigertriever registry study
Neurovascular device maker Rapid Medical said it launched a registry study of its Tigertreiver controllable stent retriever. The Israel-based company touts the Tigertriever as the only controllable, fully-visible stent retriever which can be adjusted by the physician to fit in the dimensions of the blocked blood vessel. The newly launched European multi-center registry study looks to enroll patients in France and Switzerland, and will be the 1st to examine the use of the Tigertriever in a real-life setting. The company said it has enrolled its 1st patient in the trial at Switzerland’s Cantonal Hospital of L...
Source: Mass Device - September 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Catheters Clinical Trials Stents rapidmedical Source Type: news

Virtual brain lab brings together leading neuroscientists across the world
(Simons Foundation) Twenty one leading neuroscience groups from around the world have formed a 'virtual brain lab' to test how the brain controls learning and decision making. The £ 10 million International Brain Lab brings together groups from UK, USA, France, Switzerland and Portugal to uncover how complex networks of brain cells support our ability to learn and make decisions. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 19, 2017 Category: International Medicine & Public Health Source Type: news

Urovant Sciences Appoints Keith A. Katkin as Chief Executive Officer
Former CEO of Avanir Pharmaceuticals joins Roivant family of companies Plans to initiate confirmatory Phase 3 program of vibegron by early 2018 BASEL, Switzerland, Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Urovant Sciences, a globa... Biopharmaceuticals, Urology, Personnel Urovant Sciences, Vibegron (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 18, 2017 Category: Pharmaceuticals Source Type: news

BioVentrix announces the 1st Revivent TC(TM) TransCatheter Ventricular Enhancement procedure for Ischemic Cardiomyopathy treatment at the University Heart Center Zurich in Switzerland
SAN RAMON, Calif., and ZURICH, Sept. 18, 2017 -- (Healthcare Sales & Marketing Network) -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the first clinical use of its closed-ch... Devices, Interventional, Cardiology BioVentrix, Revivent TC, TransCatheter, Ventricular Enhancement (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 18, 2017 Category: Pharmaceuticals Source Type: news

A new approach to high insulin levels
(Universit é de Gen è ve) Diabetes is characterised by a deficiency of insulin. The opposite is the case in congenital hyperinsulinism: patients produce the hormone in excessive quantities. This leads to chronic hypoglycaemia. The disorder can lead to serious brain damage and even death in the worst cases. A team at the University of Geneva (UNIGE), Switzerland, supported by the Swiss National Science Foundation has succeeded in describing the effects of a frequent genetic mutation in cases of congenital hyperinsulinism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2017 Category: International Medicine & Public Health Source Type: news

People in Switzerland Want to Know Who Is Clogging Their Toilets With Wads of Cash
(GENEVA) — Talk about flush with cash. A Geneva official has confirmed a newspaper report that said wads of cut-up 500-euro notes (about $600 each) mysteriously turned up jammed into the toilets of three neighborhood restaurants and a bank in separate episodes in recent months.Prosecutor’s office spokesman Henri Della Casa confirmed Friday’s report in the Tribune de Geneve, saying the shredded notes were once worth tens of thousands of euros in total. Preliminary clues from an investigation suggested the bounty once belonged to unnamed “Spanish women who had placed the loot in a Geneva vault several...
Source: TIME.com: Top Science and Health Stories - September 16, 2017 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized APW onetime Switzerland Source Type: news

Neovii Pharmaceuticals AG Announces New CEO
RAPPERSWIL, Switzerland, September 15, 2017 -- (Healthcare Sales & Marketing Network) -- Alexandre Sudarskis, Chief Executive Officer (CEO) of Neovii Pharmaceuticals will step down as CEO having reached retirement age. Neovii Pharmaceuticals appointed Jue... Biopharmaceuticals, Personnel Neovii Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 15, 2017 Category: Pharmaceuticals Source Type: news

Novartis' Cosentyx ® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Novartis has announced, first of its kind Phase III data showing Cosentyx® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland. (Source: World Pharma News)
Source: World Pharma News - September 15, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Santhera shares plummet after negative CHMP opinion
ZURICH (Reuters) - Swiss drugmaker Santhera's shares plunged nearly 60 percent in early trading on Friday, after a European panel recommended against approving one of its drugs to be used in patients with Duchenne muscular dystrophy (DMD). (Source: Reuters: Health)
Source: Reuters: Health - September 15, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nestl é Just Announced a Huge Blue Bottle Coffee Deal. What’s That?
Nestlé doubled down on its coffee business Thursday, acquiring a majority stake in high-end coffee brand Blue Bottle Coffee. The Swiss food and drink company is taking 68% of Blue Bottle for about $425 million, according to the Wall Street Journal. Nestlé’s stock is so far even on the deal just before market close on Thursday. Blue Bottle Coffee, based in Oakland, California, has about 40 locations in San Francisco, Los Angeles, New York, Washington, D.C. and Tokyo. But what makes the trendy coffee shop special enough that Nestlé wants in? Here’s what you need to know about Blue Bottle Coff...
Source: TIME.com: Top Science and Health Stories - September 14, 2017 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Coffee mergers and acquisitions nestle onetime Source Type: news

Halozyme to license drug delivery tech to Roche, Bristol-Myers
(Reuters) - U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker Roche in separate collaborations. (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

New book explores how the human brain can overcome any condition
(Wyss Center for Bio and Neuroengineering) In his new book 'Your brain knows more than you think,' the neuroscientist Professor Niels Birbaumer, a Senior Research Fellow at the Wyss Center, in Geneva, Switzerland, investigates the limitless capacity of the brain to remold itself. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - September 14, 2017 Category: International Medicine & Public Health Source Type: news

Derivation of a frailty index from the resident assessment instrument - home care adapted for Switzerland: a study based on retrospective data analysis - Ludwig C, Busnel C.
BACKGROUND: The screening of frail individuals at risk for functional health decline and adverse health outcomes lies in the evolving agenda of home care providers. Such a screening can be based on a frailty index (FI) derived from data collected with inte... (Source: SafetyLit)
Source: SafetyLit - September 13, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Double agents: Vessels that help cancers spread can also boost immunotherapy
(Ecole Polytechnique F é d é rale de Lausanne) Scientists from Switzerland and the US have shown that lymphatic vessels can enable both metastasis and T-cell invasion, opening new paths for cancer immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 13, 2017 Category: Cancer & Oncology Source Type: news

A new tool for tracking biological age at every level -- Young.AI beta
(InSilico Medicine, Inc.) Insilico Medicine launched the Beta 1.0 version of YOUNG.AI on September 12th, 2017 at the 4th Aging Research for Drug Discovery Forum and the Artificial Intelligence and Blockchain for Healthcare Forum in Basel, Switzerland. The beta 1.0 version features deep learned photographic and basic blood biochemistry-based predictors of age as well as the ability to track drug and supplement intake. Future updates will include multiple other data types ranging from medical imaging and brain activity readings to social circle and behavior. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 12, 2017 Category: International Medicine & Public Health Source Type: news

Best of ESMO 2017 Congress
(European Society for Medical Oncology) ESMO 2017 was a truly global event with nearly 24,000 participants from 131 countries. The ten countries with the most delegates were the USA, France, Spain, UK, Germany, Italy, Switzerland, China, Japan, and Russia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 12, 2017 Category: Cancer & Oncology Source Type: news

Aluminum salts in deodorants caused CANCER, and Switzerland may be the first nation in the world to BAN them
(Natural News) Switzerland is slated to become the first country to ban deodorants that contain aluminum salts. This, following results of a 2016 study indicating that the toxic chemicals may play a role in breast cancer onset. The country’s National Council voted 126 to 58 in favor of approving a bill instructing the Federal Council to consider... (Source: NaturalNews.com)
Source: NaturalNews.com - September 11, 2017 Category: Consumer Health News Source Type: news

Roche shares hit by trial flops, fears over biosimilar defense
ZURICH (Reuters) - Roche shares fell in early trading on Monday after trial failures added to the Swiss drugmaker's challenge of replacing patent-expired medicines with lucrative new drugs. (Source: Reuters: Health)
Source: Reuters: Health - September 11, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

The 2017 Balzan Prizewinners announced today in Milan
(Gold Communications) The names of the 2017 Balzan Prizewinners were disclosed today in a public announcement: 750,000 Swiss Francs (approx. € 660,000; $790,000) for each of the subjects. Half of the amount must be destined by the winners to research projects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

Novartis posts a win, Roche a flop in skin cancer trials
ZURICH/MADRID (Reuters) - Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. (Source: Reuters: Health)
Source: Reuters: Health - September 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

PSI CRO growing abroad – and in Durham
The Triangle is a hotbed of contract research organizations, and Switzerland-based PSI CRO, which opened a Durham office in April of last year, is continuing to expand its presence abroad and locally. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 8, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

PSI CRO growing abroad – and in Durham
The Triangle is a hotbed of contract research organizations, and Switzerland-based PSI CRO, which opened a Durham office in April of last year, is continuing to expand its presence abroad and locally. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 8, 2017 Category: Biotechnology Authors: Jennifer Henderson Source Type: news

7 medtech stories we missed this week: Sept. 8, 2017
[Image from unsplash.com]From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating a pediatric capability for its BrainScope One medical neurotechnology. The technology is an FDA-cleared handheld medical device that is designed to assess the full spectrum of traumatic brain injury. The company sa...
Source: Mass Device - September 8, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiac Assist Devices Cardiovascular Clinical Trials Diagnostics Food & Drug Administration (FDA) Imaging mHealth (Mobile Health) Neurological Regulatory/Compliance Research & Development Spinal AliveCor Bonesupport Bra Source Type: news

Deals this week: Mundipharma Medical Company, Cooper Pharmal Sarl, Merck
Mundipharma Medical Company will exclusively distribute INVOKANA (canagliflozin) and VOKANAMET (canagliflozin and metformin) in the European Economic Area (EEA) and Switzerland, under an agreement signed with drug developer and manufacturer Janssen P … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Researchers break through the wall in bacterial membrane vesicle research
(University of Tsukuba) Japanese and Swiss researchers used advanced imaging techniques to investigate the formation of membrane vesicles in a Gram-positive bacterium, a process that is poorly understood, particularly in bacteria with thick cell walls. The consortium showed that membrane vesicle formation was triggered by an enzyme called endolysin that damages the cell wall to create holes that allow the release of membrane vesicles. This mechanism could be exploited for the mass production of bacterial vesicles. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 7, 2017 Category: Biology Source Type: news

NAS, NAM Members Receive Lasker Awards
The Albert and Mary Lasker Foundation announced today that NAS member Michael N. Hall, professor, Biozentrum, University of Basel, Switzerland, is the recipient of the 2017 Albert Lasker Basic Medical Research Award for"discoveries concerning the nutrient-activated TOR proteins and their central role in the metabolic control of cell growth." Dual NAS/NAM member Douglas Lowy, acting director of the National Cancer Institute, has been awarded the 2017 Lasker~DeBakey Clinical Medical Research Award, along with John T. Schiller of the NCI, for"technological advances that enabled development of HPV vaccines for p...
Source: News from the National Academies - September 6, 2017 Category: Science Source Type: news

3 Scientists and Planned Parenthood Win Lasker Prizes for Medical Research
(NEW YORK) — Two scientists who paved the way for widely used vaccines and another who discovered key players in cell growth have been awarded prestigious medical research awards. The Albert and Mary Lasker Foundation also announced Wednesday that it was giving its public service award to Planned Parenthood. Each award includes a $250,000 honorarium. The foundation’s clinical research award is shared by Dr. Douglas Lowy and John Schiller of the U.S. National Cancer Institute. In the early 1990s they began work that would eventually lead to vaccines against human papillomavirus, or HPV, which causes cervical can...
Source: TIME.com: Top Science and Health Stories - September 6, 2017 Category: Consumer Health News Authors: Malcolm Ritter / AP Tags: Uncategorized awards medical research onetime Planned Parenthood Science Source Type: news

Kapanu 3D gives patients virtual view of expected health
Kapanu 3D, created by Swiss researchers, allows adults seeking a Hollywood smile to choose their desired smile right in front of their eyes - based on current scans of their mouth. (Source: the Mail online | Health)
Source: the Mail online | Health - September 6, 2017 Category: Consumer Health News Source Type: news

Nigeria: Experts Fault Proposed Field Trial of Genetically Modified Cassava
[Guardian] Abuja -Experts have condemned an alleged move by the International Institute of Tropical Agriculture, (IITA) and Zurich, Switzerland-based ETHZ Laboratories to carry out confined field trial of genetically modified cassava in Nigeria. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 6, 2017 Category: African Health Source Type: news

The bacteria responsible for legionellosis modulates the host cell metabolism to its advantage
(Institut Pasteur) Scientists at the Institut Pasteur, CNRS and Inserm, together with a team from Switzerland, have shown that the bacterial pathogen Legionella pneumophila has developed a specific strategy to target the host cell mitochondria, the organelles in charge of cellular bioenergetics. This work provides precious information on how a pathogen manipulates the cellular metabolism to replicate intracellularly, and proposes a new concept of protection of host cells from Legionella-induced mitochondrial changes in order to fight infection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 6, 2017 Category: International Medicine & Public Health Source Type: news

EMBO at Basel Life, a new conference on current and emerging life science research
(EMBO) EMBO and Basel Life are pleased to announce the EMBO at Basel Life conference, taking place at the Congress Center Basel, Switzerland, from Sept. 10-13, 2017. A committee of leading scientists has organized this international and broad-scope scientific conference on current and emerging life science research to be held as part of Basel Life. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 6, 2017 Category: Biology Source Type: news

FDA grants rare paediatric disease designation for Novimmune ’s HLH emapalumab treatment
Swiss biopharmaceutical company Novimmune has received rare paediatric disease designation for its lead drug emapalumab from the US Food and Drug Administration (FDA) to treat patients with primary haemophagocytic lymphohistiocytosis (HLH). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 5, 2017 Category: Pharmaceuticals Source Type: news

Novartis Names Drugs Chief as CEO to Deliver Return to Growth Novartis Names Drugs Chief as CEO to Deliver Return to Growth
Novartis CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 5, 2017 Category: Consumer Health News Tags: Pharmacist News Source Type: news

Novartis names chief to replace Jimenez who is to step down
Swiss group’s head of drug development Vas Narasimhan succeeds long-serving boss (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 4, 2017 Category: Pharmaceuticals Source Type: news

Novartis names drugs chief as CEO to deliver return to growth
ZURICH (Reuters) - Novartis CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth. (Source: Reuters: Health)
Source: Reuters: Health - September 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Africa: Zimbabwe to Chair 2018 World Health Assembly
[The Herald] Zimbabwe has been elected to chair the 71st World Health Assembly scheduled to take place between 21 and 26 May 2018 in Geneva, Switzerland. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 4, 2017 Category: African Health Source Type: news

Novartis's Jimenez stepping down, Narasimhan named new CEO
ZURICH (Reuters) - Novartis Chief Executive Joseph Jimenez will retire in 2018, with chief drug developer Vasant Narasimhan taking over as CEO starting in February, the Swiss drugmaker said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - September 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Roche Diagnostics India looks at 15 per cent IVD market share in 2 years
Roche Diagnostics is part of Swiss healthcare major Roche. It sells devices and equipment to labs and hospitals and is mainly present in the business-to-business space. (Source: The Economic Times)
Source: The Economic Times - September 3, 2017 Category: Consumer Health News Source Type: news

Profit on $475,000 Novartis Cancer Drug Could Be a While Coming Profit on $475,000 Novartis Cancer Drug Could Be a While Coming
Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Legal cannabis oil has Scott Disick and Snoop Dogg as fans
EXCLUSIVE SwissX is produced in the Swiss alps due to the growth of organic cannabidiol-rich plants. Unlike cannabis, SwissX does not contain the compound that causes people to hallucinate. (Source: the Mail online | Health)
Source: the Mail online | Health - September 1, 2017 Category: Consumer Health News Source Type: news

Profit on $475,000 Novartis cancer drug could be a while coming
ZURICH (Reuters) - Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Nestle shuts Swiss skin health products factory
ZURICH (Reuters) - Nestle said on Thursday it was closing a Swiss factory which makes products for its skin health business, responding to a slowdown in a business once seen as one of its rising stars. (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Swiss cheese found to contain powerful probiotic that promotes longevity
(Natural News) Researchers have found that cheese can now be considered a superfood – as long as it’s Swiss cheese. The bacterium Propionibacterium freudenreichii, which is used in the fermentation of Emmentaler – the proper name of Swiss cheese, because it came from the Emmental region of Switzerland – is found to be beneficial to... (Source: NaturalNews.com)
Source: NaturalNews.com - August 30, 2017 Category: Consumer Health News Source Type: news